| Document |
Document Title |
|
WO/2002/017937A1 |
The present invention refers to extracts from the fungus Guignardia sp., and also a new isolate compound from the aforementioned extract, both having antimicrobial activities, and their use in pharmaceutical compositions. The new compoun...
|
|
WO/2002/016316A1 |
The invention provides for a non-steroidal compound having the formula [I], wherein R?e¿ and 'R?e¿ are OH, optionally independently etherified or esterified; Z is -CH¿2?- or -CH¿2?CH¿2?-; R?1¿ is H, halogen, CF¿3?, or (1C-4C)alkyl...
|
|
WO/2002/016315A1 |
The invention relates to semicarbicides of the general formula (I), wherein R?1¿, R?2¿, R?3¿, R?4¿ and I are defined as in claim 1. The compounds of formula (I) can be used as active ingredients for medicaments in human and veterinar...
|
|
WO/2002/016318A1 |
The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pa...
|
|
WO/2002/016319A1 |
The present invention relates to thiourea compounds and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as an antagonist against vanilloid receptor (VR) and the pharmaceutical compositio...
|
|
WO/2002/014265A1 |
Urea derivatives represented by the following general formula (1) or pharmaceutically acceptable salts thereof: (1) wherein each symbol is as defined in the description. Because of having a C5a receptor antagonism, these compounds are us...
|
|
WO/2002/014302A1 |
A process for synthesizing an alkylene carbonate from an alkylene oxide by using supercritical carbon dioxide without resort to any metal catalysts. This process comprises reacting an alkylene oxide with carbon dioxide of 60 kg/cm?2¿ or...
|
|
WO/2002/014259A1 |
Compounds of the general formula [I], salts or solvates thereof, or prodrugs of them; pharmaceutical compositions (including calcium receptor antagonists) containing the compounds, salts, solvates or prodrugs; and intermediates of the co...
|
|
WO/2002/014267A1 |
The present invention relates to compounds of formula (I) wherein U, V, W, A?1¿, A?2¿, A?3¿, A?4¿, A?5¿, A?6¿, m and n are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically accep...
|
|
WO/2002/012224A2 |
Substituted N-substituted alkoxyphenyl compounds, compositions containing them, and methods of making and using them.
|
|
WO/2002/011715A2 |
The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R¿1?, R¿2?, R¿3?, R¿4? and R¿5...
|
|
WO/2002/012166A2 |
The invention provides triamine derivative melanocortin receptor ligands of the formula (1), wherein R?1¿ to R?8¿ and n have the meanings provided herein. The invention further provides methods of using the ligands to alter or regulate...
|
|
WO/2002/012190A2 |
Substituted non-imidazole aryloxypiperidine compounds, compositions containing them, and methods of making and using them to treat or prevent histamine-mediated conditions.
|
|
WO/2002/012214A2 |
Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
|
|
WO/2002/012215A1 |
A process for the preparation of 14$g(b)-hydroxy-1,4-carbonate-deacetylbaccatin III and intermediates useful for the preparation of novel taxan derivatives with antitumor activity are disclosed.
|
|
WO/2002/012247A1 |
The invention relates to a method for the preparation of compound of formula (1). The invention further relates to the previously unknown compounds of formulas (5 and 6) as intermediates in the production of benzodiazepines of formula (1).
|
|
WO/2002/010150A1 |
± 3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, a process for the optical resolution thereof and their use as intermediates for the prepartion of (-) 3-(4-phenyl-1-piperazinyl)-1,2-propanediol (levodropropizine) and salts t...
|
|
WO/2002/010096A1 |
One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing cataly...
|
|
WO/2002/010149A1 |
(S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals useful as antitussive agents and as intermediates for the preparation of levodropropizine and the salts thereof, as well as a process for the preparation of said acetals, are ...
|
|
WO/2002/010106A1 |
The invention provides novel processes for the preparation of fluorinated acyl fluorides and fluorinated vinyl ethers, i.e., a process for the preparation of fluorinated acyl fluorides (3) which comprises reacting a compound (1) having a...
|
|
WO/2002/009688A1 |
This invention relates to the use of compounds as inhibitors of the fattty acid synthase FabH.
|
|
WO/2002/010146A1 |
Compounds of formula (I) in which: each A is independently hydrogen, C¿1-6?alkyl optionally substituted by hydroxyl, C¿1-6?alkoxy, C¿1-6?alkenyl or C¿1-6?acyl group or a halogen atom or hydroxyl, CN or CF¿3? group; R3 is hydrogen, m...
|
|
WO/2002/006265A1 |
The invention relates to chiral compounds of formula (I) wherein Y?1¿, Y?2¿, Y?3¿, Y?4¿, X?1¿, X?2¿, X?3¿ and X?4¿ have the meaning given in claim 1, to liquid crystalline mixtures comprising at least one chiral compound of formu...
|
|
WO/2002/006189A2 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salt and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associa...
|
|
WO/2002/006215A1 |
A compound which is an arylsulfonyl propanoic acid derivative of formula (I) : CH¿2?R¿1? XC(O)-C(OH)-SO¿2?-C¿6?H¿4?-N(R¿2?)COA (I) wherein X is HO-NH- or HO- , R1 is selected from -O-Ph, -S-Ph, -S-Het, -Hyd or -CH¿2?-Hyd, wherein ...
|
|
WO/2002/006213A2 |
The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters ...
|
|
WO/2002/003995A2 |
The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.
|
|
WO/2002/004403A1 |
The invention relates to substituted piperazine derivatives of general formula (I), wherein R?1¿ to R?7¿ have the meanings given in claim no. 1, isomers thereof and salts thereof, especially physiologically compatible salts thereof, wh...
|
|
WO/2002/004406A2 |
The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocyline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2002/004407A2 |
The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplas...
|
|
WO/2002/002546A1 |
The invention provides intermediates from which $g(a)-keto amide compounds having protease inhibiting activity can be prepared extremely economically and stereoselectively. Specifically, epoxycarboxylic acid amides, azides and amino alco...
|
|
WO/2002/002119A1 |
This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
|
|
WO/2002/002513A1 |
The invention provides compounds of formula I wherein R?1¿ is optionally substituted C¿1?-¿6?alkyl, optionally substituted C¿3-7? cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; n is 0, 1 or 2; and Y i...
|
|
WO/2002/002507A1 |
The invention relates to an oxidative colouring agent for keratin fibres, in particular hair, based on a developing agent-coupling agent combination, which contains as a developing agent, at least one 2-hydroxy-5-amino-biphenyl derivativ...
|
|
WO/2002/000606A1 |
A novel biphenyl compound having GPR14 antagonism. It is a compound represented by the formula (I) or a salt thereof, wherein R?1¿ represents hydrogen, etc.; X represents 1 to 12 spacers; A represents amino, etc.; R?2¿ and R?3¿ each r...
|
|
WO/2002/000590A1 |
The invention is directed to the cross-metathesis and ring-closing metathesis reactions between geminal disubstituted olefins and terminal olefins, wherein the reaction employs a Ruthenium or Osmium metal carbene complex. Specifically, t...
|
|
WO/2001/098291A2 |
It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inf...
|
|
WO/2001/098248A2 |
The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula (I), or a tautomer of said compound, or a pharmaceutically acceptable salt, solvate or prodru...
|
|
WO/2001/096494A1 |
A unique class of chiral additive materials is disclosed for use in cholesteric displays that possess a helical twist power substantially independent of temperature. The additives have a solubility and a helical twist power large enough ...
|
|
WO/2001/096285A1 |
The present invention relates to compound of formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿ and n are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof...
|
|
WO/2001/096589A1 |
The invention relates to a substituted methylenedioxy lignan compound. Preferably this compound is extracted from Phyllantus urinaria, a weed abundantly found in Indian subcontinent. Extraction is carried out by first preparing the alcoh...
|
|
WO/2001/094295A1 |
The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, methods of treatment administering these compounds to mammalian hosts, and processes for their preparation. Specifically, the inv...
|
|
WO/2001/092263A1 |
The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in...
|
|
WO/2001/090051A1 |
The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula (I) wherein X and R?1¿ to R?5¿ are as defined in the description and in the claims, as well as hydrates or solvates and/or physiologica...
|
|
WO/2001/090099A1 |
This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
|
|
WO/2001/087824A2 |
7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.
|
|
WO/2001/087838A1 |
The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R?1¿, R?2¿, R?3¿, R?4¿, R?5¿,...
|
|
WO/2001/087822A1 |
The invention relates to phenyl-propargylether derivatives of general formula (I) including the optical isomers thereof and mixtures of such isomers, wherein R¿1? is hydrogen, alkyl, cycloalkyl or optionally substituted aryl, R¿2? and ...
|
|
WO/2001/087894A1 |
Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected fro...
|
|
WO/2001/087895A1 |
Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a l-labile, 10-hydroxy, ...
|
